NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis $6.73 -0.06 (-0.88%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.73 0.00 (0.00%) As of 04/25/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Wave Life Sciences Stock (NASDAQ:WVE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Wave Life Sciences alerts:Sign Up Key Stats Today's Range$6.54▼$6.8250-Day Range$5.48▼$11.3352-Week Range$4.25▼$16.74Volume1.04 million shsAverage Volume1.22 million shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$22.18Consensus RatingBuy Company OverviewWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More… Wave Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreWVE MarketRank™: Wave Life Sciences scored higher than 86% of companies evaluated by MarketBeat, and ranked 93rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingWave Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Wave Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Wave Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 16.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Wave Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.79% of the float of Wave Life Sciences has been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted10.79% of the float of Wave Life Sciences has been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.23 News SentimentWave Life Sciences has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Wave Life Sciences this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 2 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,720,154.00 in company stock.Percentage Held by Insiders29.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Wave Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesWave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.18 Consensus Target Price from AnalystsApril 25 at 1:53 AM | americanbankingnews.comShort Interest in Wave Life Sciences Ltd. (NASDAQ:WVE) Increases By 19.2%April 21, 2025 | americanbankingnews.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 27, 2025 | Crypto Swap Profits (Ad)Wave Life Sciences price target lowered to $19 from $22 at B. RileyApril 11, 2025 | markets.businessinsider.comWedbush starts RNA-focused standout Wave Life Sciences with an OutperformApril 8, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)April 2, 2025 | markets.businessinsider.comWave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531March 27, 2025 | seekingalpha.comWave Life Sciences unveils Phase II data for DMD therapy, WVE-N531March 27, 2025 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? Wave Life Sciences' stock was trading at $12.37 at the beginning of the year. Since then, WVE stock has decreased by 45.6% and is now trading at $6.73. View the best growth stocks for 2025 here. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings data on Tuesday, March, 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative trailing twelve-month return on equity of 280.57%. Read the conference call transcript. Who are Wave Life Sciences' major shareholders? Wave Life Sciences' top institutional shareholders include Rhumbline Advisers (0.09%) and James J. Burns & Company LLC (0.08%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Paul Bolno, Chandra Vargeese, Kyle Moran, Christian O Henry and Chris Francis. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Wave Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings3/04/2025Today4/27/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Stock Price Target$22.18 High Stock Price Target$36.00 Low Stock Price Target$15.00 Potential Upside/Downside+229.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-66.50% Pretax Margin-265.84% Return on Equity-280.57% Return on Assets-52.90% Debt Debt-to-Equity RatioN/A Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual Sales$108.30 million Price / Sales9.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book16.83Miscellaneous Outstanding Shares153,486,000Free Float108,137,000Market Cap$1.03 billion OptionableOptionable Beta-0.93 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:WVE) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Wave Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.